2,014
Participants
Start Date
February 6, 2023
Primary Completion Date
August 22, 2023
Study Completion Date
December 7, 2023
Gamma Variant RBD-based ARVAC-CG vaccine
Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
Omicron Variant RBD-based ARVAC-CG vaccine
Vaccine containing 50 µg of antigen + Alum. Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
Bivalent RBD-based ARVAC-CG vaccine
Vaccine containing 25 µg of gamma antigen + 25 µg of omicron antigen + Alum Schedule: One booster dose of vaccine Administration route: intramuscular (IM) injection
Placebo (Alum)
Schedule: One dose of placebo in a crossover design Administration route: intramuscular (IM) injection
Fundación Huesped, Buenos Aires
Centro de Investigaciones Clínicas Belgrano (CICB), Buenos Aires
FP Clinical Pharma, Buenos Aires
Centro Médico Dra. Laura Maffei - Investigación Clínica Aplicada, Ciudad de Buenos Aires
Vacunar S.A., Buenos Aires
"Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno - CEMIC", Argentina
Instituto Medico Platense, Buenos Aires
ICSAL Salta, Salta
Clinica Privada del Sol, Córdoba
Instituto de Investigaciones Clínicas de Mar del Plata, Buenos Aires
Centro Clínica del Niño y la Familia, Buenos Aires
Universidad Nacional de San Martín (UNSAM)
UNKNOWN
National Council of Scientific and Technical Research, Argentina
OTHER_GOV
Laboratorio Pablo Cassará S.R.L.
INDUSTRY
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
OTHER